DR Ka-On Lam


MBBS (H.K.), FRCR (U.K.), FHKCR, FHKAM (Radiology)
Clinical Assistant Professor

E-mail: lamkaon@hku.hk



Dr. Ka-On Lam is currently Clinical Assistant Professor of the Department of Clinical Oncology, The University of Hong Kong. He graduated from The University of Hong Kong in 2005 and joined the Department of Clinical Oncology in Tuen Mun Hospital in 2006. He was awarded the Frank Doyle Medal and the Rohan Williams Medal for his outstanding performance in the fellowship examination of The Royal College of Radiologists. He joined the Department of Clinical Oncology, LKS Faculty of Medicine HKU in 2011. He was awarded the University of Hong Kong Overseas Fellowship in 2013 which funded his elective with Prof. David Cunningham and Dr. Ian Chau in the GI unit of the Royal Marsden, UK.

Dr. Lam is actively involved in teaching of medical students and nurses. His research interests include gastroesophageal and colorectal cancer. He published in peer-review journals and has presented in various local and international cancer conferences. He is now working on various clinical trials including intraperitoneal chemotherapy for metastatic gastric cancer and the evaluation of predictive and prognostic markers for preoperative chemo-irradiation in rectal cancer. Pattern of failure and radiation induced toxicity in chemoradiation for esophageal and rectal cancer are his other areas of interest.


Research Interest:

My research interests include gastrointestinal and nasopharyngeal cancers with special focus on novel treatment strategies and molecular basis of cancer. I am now working on various prospective projects including intraperitoneal chemotherapy for metastatic gastric cancer and the evaluation of predictive and prognostic markers for preoperative chemoirradiation in rectal cancer.


Selected Publications:

  • Lee VH, Kwong DL, Leung TW, Choi CW, Lai V, Ng L, Lam KO, Ng SC, Sze CK, Tong CC, Ho PP, Chan WL, Wong LS, Leung DK, Chan SY, Khong PL. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Oncotarget. 2017 Jan 17;8(3):5292-5308. DOI:10.18632/oncotarget.14137.

  • Yeo W, Lam KO, Law AL, Lee CC, Chiang CL, Au KH, Mo FK, So TH, Lam KC, Ng WT, Li L. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associatied risk factors. Hong Kong Med J. 2016 Dec 14. DOI:10.12809/hkmj164885.

  • Lam KO, Lee KC, Chiu J, Lee VH, Leung R, Choy TS, Yau T. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong. Postgrad Med J. 2016 Nov 11. pii: postgradmedj-2016-134547. DOI:10.1136/postgradmedj-2016-134547.

  • Lee VH, Kwong DL, Leung TW, Ng SC, Lam KO, Tong CC, Sze CK. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2016 Oct 13; 274:1067. DOI:10.1007/s00405-016-4339-0.

  • Zheng H, Dai W, Cheung AK, Ko JM, Kan R, Wong BW, Leong MM, Deng M, Kwok TC, Chan JY, Kwong DL, Lee AW, Ng WT, Ngan RK, Yau CC, Tung S, Lee VH, Lam KO, Kwan CK, Li WS, Yau S, Chan KW, Lung ML. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11283-11288.

  • Lee V, Lam KO, Kwong D, Leung TW. Radiation recall after capecitabine in a patient with recurrent nasopharyngeal carcinoma: a case report. J Med Case Rep. 2016 Sep 7;10(1):247. DOI:10.1186/s13256-016-1033-1.

  • Ho S, Ip W, Chu S, Chan S, Lee B, Chan B, Lee J, Flynn B, Ho W, Sin J, Kwong DL, Leung TW, Lam KO. Treatment Regret in Long-term Survivors of Nasopharyngeal Carcinoma Treated with Radical Radiotherapy. Clin Oncol (R Coll Radiol). 2016 Aug 23. pii: S0936-6555(16)30267-9. DOI:10.1016/j.clon.2016.08.006.

  • Lee VH, Lo AW, Leung CY, Shek WH, Kwong DL, Lam KO, Tong CC, Sze CK, Leung TW. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intersity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. PLoS One. 2016 Jun 24:11(6):e0157969. DOI:10.1371/journal.pone.0157969. eCollection 2016.

  • Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, Sze CK, Ng S, Leung TW, Lee A. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma. Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e52-60. DOI:10.1016/j.clon.2016.05.004.

  • Lam KO, Lee AW, Ng WT, Hopkins KI. The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. Chin Clin Oncol. 2016 Apr;5(2):27. DOI:10.21037/cco.2016.03.02.